David Staneck, MD
Aerospace Medicine · Cherry Point, NCNPI 1730181199
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,935 of the $6,752 with a category attached, or 73.1%. It is spread thinly across 36 manufacturers, the largest accounting for just 14.4%. Reporting peaked in 2023 at $2,233 and has fallen 53.5% since, to $1,037 in 2025.
Across 227 payments — averaging $29.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$975
- Valencia Technologies Corporation$880
- Pfizer$693
- Astellas Pharma US Inc$598
- Boston Scientific$393
- Johnson & Johnson$385
- plus $3K from 30 others
What the payments were for
- Travel & lodging$1,33420%
- Food & beverage$4,93573%
- Education$4667%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 14 | $975 |
| Valencia Technologies Corporation | 3 | $880 |
| Pfizer | 23 | $693 |
| Astellas Pharma US Inc | 28 | $598 |
| Boston Scientific | 11 | $393 |
| Johnson & Johnson | 14 | $385 |
| AbbVie | 21 | $352 |
| Dendreon Pharmaceuticals LLC | 12 | $298 |
| Bayer | 12 | $270 |
| Endo Pharmaceuticals Inc. | 12 | $234 |
| Myriad Genetic Laboratories, Inc. | 12 | $221 |
| Myovant Sciences Inc. | 10 | $146 |
| Travere Therapeutics, Inc. | 9 | $146 |
| Olympus America Inc. | 4 | $107 |
| Accord Healthcare, Inc. | 5 | $102 |
| Abbott | 1 | $93 |
| Progenics Pharmaceuticals, Inc. | 3 | $89 |
| Convatec Inc. | 3 | $82 |
| AstraZeneca | 3 | $81 |
| Endo USA, Inc. | 3 | $78 |
| Urogen Pharma, Inc. | 3 | $68 |
| Amgen | 3 | $66 |
| 180 Medical, Inc. | 2 | $56 |
| Blue Earth Diagnostics | 1 | $43 |
| Vertex | 2 | $42 |
| Antares Pharma, Inc. | 2 | $38 |
| Axonics, Inc. | 2 | $36 |
| Telix Pharmaceuticals | 1 | $30 |
| Procept Biorobotics Corporation | 1 | $28 |
| Novartis | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Coloplast | 1 | $17 |
| Immunitybio, Inc. | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- eCoin Device Kit$755
- UroLift$740
- REZUM$121
How this compares
Too few aerospace medicine providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 12 | $173,727 |
| GemtesaVibegron | 166 | $161,037 |
| XtandiEnzalutamide | 11 | $153,610 |
| MyrbetriqMirabegron | 152 | $130,643 |
| Tamsulosin Hcl | 898 | $15,695 |
| Solifenacin Succinate | 240 | $10,001 |
| Finasteride | 485 | $7,129 |
| Potassium Citrate ErPotassium Citrate | 35 | $3,718 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 128 | $3,129 |
| Oxybutynin Chloride ErOxybutynin Chloride | 133 | $2,660 |
| Methenamine Hippurate | 35 | $2,563 |
| Trospium Chloride | 34 | $2,455 |
| Cephalexin | 251 | $2,211 |
| Tolterodine Tartrate ErTolterodine Tartrate | 44 | $1,852 |
| Dutasteride | 36 | $1,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $598 | $284,253163 claims |
| Johnson & JohnsonErleada | $385 | $173,72712 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $15 | $161,037166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few aerospace medicine providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other aerospace medicine in Cherry Point
- Manoj MathewJacksonville$555
- Andrew PaulHavelock$145
- Mark SwedenburgGoldsboro$142
- Jacob DuongCamp Lejeune$102
- Rachel PalmerSeymour Johnson Afb$49
- Greg RogersJacksonville$46
- Noah KainradJacksonville$16
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.